<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34592758</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2473-9537</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Blood advances</Title>
          <ISOAbbreviation>Blood Adv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evans syndrome in adults: an observational multicenter study.</ArticleTitle>
        <Pagination>
          <StartPage>5468</StartPage>
          <EndPage>5478</EndPage>
          <MedlinePgn>5468-5478</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1182/bloodadvances.2021005610</ELocationID>
        <Abstract>
          <AbstractText>Evans syndrome (ES) is a rare condition, defined as the presence of 2 autoimmune cytopenias, most frequently autoimmune hemolytic anemia and immune thrombocytopenia (ITP) and rarely autoimmune neutropenia. ES can be classified as primary or secondary to various conditions, including lymphoproliferative disorders, other systemic autoimmune diseases, and primary immunodeficiencies, particularly in children. In adult ES, little is known about clinical features, disease associations, and outcomes. In this retrospective international study, we analyzed 116 adult patients followed at 13 European tertiary centers, focusing on treatment requirements, occurrence of complications, and death. ES was secondary to or associated with underlying conditions in 24 cases (21%), mainly other autoimmune diseases and hematologic neoplasms. Bleeding occurred in 42% of patients, mainly low grade and at ITP onset. Almost all patients received first-line treatment (steroids with or without intravenous immunoglobulin), and 23% needed early additional therapy for primary refractoriness. Additional therapy lines included rituximab, splenectomy, immunosuppressants, thrombopoietin receptor agonists, and others, with response rates &gt;80%. However, a remarkable number of relapses occurred, requiring ≥3 therapy lines in 54% of cases. Infections and thrombotic complications occurred in 33% and 21% of patients, respectively, mainly grade ≥3, and correlated with the number of therapy lines. In addition to age, other factors negatively affecting survival were severe anemia at onset and occurrence of relapse, infection, and thrombosis. These data show that adult ES is often severe and marked by a relapsing clinical course and potentially fatal complications, pinpointing the need for high clinical awareness, prompt therapy, and anti-infectious/anti-thrombotic prophylaxis.</AbstractText>
          <CopyrightInformation>© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fattizzo</LastName>
            <ForeName>Bruno</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0003-0857-8379</Identifier>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Michel</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Centre de Référence Maladies Rares sur les Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil Université Paris-Est Créteil, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giannotta</LastName>
            <ForeName>Juri Alessandro</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0001-9349-1627</Identifier>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hansen</LastName>
            <ForeName>Dennis Lund</ForeName>
            <Initials>DL</Initials>
            <Identifier Source="ORCID">0000-0002-4478-1297</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arguello</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital Universitario Principe de Asturias (Alcala de Henares), Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sutto</LastName>
            <ForeName>Emanuele</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Hematology "L. e A. Seragnoli", University of Bologna, Bologna, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bianchetti</LastName>
            <ForeName>Nicola</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Ematologia, Spedali Civili di Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patriarca</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-4415-2906</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Translational Medicine, Azienda Ospedaliera-Universitaria "Maggiore della Carità", University of Eastern Piedmont, Novara, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cantoni</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Ematologia e Oncologia, Niguarda Cancer Center, Azienda Socio Sanitaria Territoriale Ospedale Niguarda, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mingot-Castellano</LastName>
            <ForeName>María Eva</ForeName>
            <Initials>ME</Initials>
            <Identifier Source="ORCID">0000-0001-9083-855X</Identifier>
            <AffiliationInfo>
              <Affiliation>Servicio de Hematología, Hospital Universitario Virgen del Rocio, Seville, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McDonald</LastName>
            <ForeName>Vickie</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Haematology, Barts Health National Health Service Trust, Queen Mary University, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Capecchi</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zaninoni</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Consonni</LastName>
            <ForeName>Dario</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-8935-3843</Identifier>
            <AffiliationInfo>
              <Affiliation>Epidemiology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vos</LastName>
            <ForeName>Josephine Mathilde</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Amsterdam University Medical Center, University of Amsterdam-Sanquin Landsteiner Laboratory, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vianelli</LastName>
            <ForeName>Nicola</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Hematology "L. e A. Seragnoli", University of Bologna, Bologna, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Frederick</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Haematology, Barts Health National Health Service Trust, Queen Mary University, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Glenthøj</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-2082-0738</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Rigshospitalet, Copenhagen, Denmark; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frederiksen</LastName>
            <ForeName>Henrik</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-8905-0220</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>González-López</LastName>
            <ForeName>Tomás José</ForeName>
            <Initials>TJ</Initials>
            <AffiliationInfo>
              <Affiliation>Servicio de Hematología, Hospital Universitario de Burgos, Burgos, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barcellini</LastName>
            <ForeName>Wilma</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Blood Adv</MedlineTA>
        <NlmUniqueID>101698425</NlmUniqueID>
        <ISSNLinking>2473-9529</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536380">Evans Syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000744" MajorTopicYN="Y">Anemia, Hemolytic, Autoimmune</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>20</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34592758</ArticleId>
        <ArticleId IdType="pmc">PMC8714709</ArticleId>
        <ArticleId IdType="doi">10.1182/bloodadvances.2021005610</ArticleId>
        <ArticleId IdType="pii">477110</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med.
1951;87(1):48-65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14782741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Audia S, Grienay N, Mounier M, Michel M, Bonnotte B. Evans’ syndrome: from diagnosis to treatment. J Clin Med.
2020;9(12):3851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7759819</ArticleId>
            <ArticleId IdType="pubmed">33260979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen DL, Möller S, Andersen K, Gaist D, Frederiksen H. Evans syndrome in adults - incidence, prevalence, and survival in a nationwide cohort. Am J Hematol.
2019;94(10):1081-1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31292991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjadj J, Aladjidi N, Fernandes H, et al. ; members of the French Reference Center for Pediatric Autoimmune Cytopenia (CEREVANCE) . Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood.
2019;134(1):9-21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30940614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannering N, Hansen DL, Frederiksen H. Evans syndrome in children below 13 years of age - a nationwide population-based cohort study. PLoS One.
2020;15(4):e0231284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7145102</ArticleId>
            <ArticleId IdType="pubmed">32271826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pincez T, Fernandes H, Leblanc T, et al. . Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden [published online ahead of print 14 January 2021]. Haematologica. doi: 10.3324/haematol.2020.271106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2020.271106</ArticleId>
            <ArticleId IdType="pubmed">33440924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel M, Chanet V, Dechartres A, et al. . The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood.
2009;114(15):3167-3172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19638626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neunert C, Terrell DR, Arnold DM, et al. . American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020;4(2):252]. Blood Adv.
2019;3(23):3829-3866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6988391</ArticleId>
            <ArticleId IdType="pubmed">31945156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jäger U, Barcellini W, Broome CM, et al. . Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev.
2020;41:100648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31839434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo B, Zaninoni A, Consonni D, et al. . Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study. Eur J Intern Med.
2015;26(8):611-615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26066399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellini W, Fattizzo B, Zaninoni A, et al. . Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood.
2014;124(19):2930-2936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25232059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed 27 February 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol.
2012;41(3):861-870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3396320</ArticleId>
            <ArticleId IdType="pubmed">22253319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renoux C, Azoulay L, Suissa S. Biases in evaluating the safety and effectiveness of drugs for covid-19: designing real-world evidence studies. Am J Epidemiol.
2021;190(8):1452-1456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7929453</ArticleId>
            <ArticleId IdType="pubmed">33564823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellini W, Zaninoni A, Fattizzo B, et al. . Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. Am J Hematol.
2018;93(9):E243-E246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29981267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannotta JA, Fattizzo B, Cavallaro F, Barcellini W. Infectious complications in autoimmune hemolytic anemia. J Clin Med.
2021;10(1):164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7796467</ArticleId>
            <ArticleId IdType="pubmed">33466516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broome CM, Cunningham JM, Mullins M, et al. . Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost.
2020;4(4):628-635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7292660</ArticleId>
            <ArticleId IdType="pubmed">32548562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berentsen S, Barcellini W, D’Sa S, et al. . Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood.
2020; 136(4):480-488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32374875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho G, Brunson A, Keegan THM, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia. Blood Cells Mol Dis.
2020;81:102388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31805473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodeghiero F. Is ITP a thrombophilic disorder?
Am J Hematol.
2016;91(1):39-45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26547507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Audia S, Bach B, Samson M, et al. . Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS One.
2018;13(11):e0207218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6224177</ArticleId>
            <ArticleId IdType="pubmed">30408135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo B. Evans syndrome and infections: a dangerous cocktail to manage with caution. Blood Transfus.
2021;19(1):5-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7850928</ArticleId>
            <ArticleId IdType="pubmed">33523800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuelson Bannow BT, Lee A, Khorana AA, et al. . Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost.
2018;16(6):1246-1249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29737593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodeghiero F, Stasi R, Gernsheimer T, et al. . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood.
2009;113(11):2386-2393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19005182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boulware R, Refaai MA. Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia?
Thromb Res.
2020;187:154-158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32004875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dada R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol.
2019;103(3):152-163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31270855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Swart L, Smith A, Johnston TW, et al. . Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol.
2015;170(3):372-383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25907546</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
